ISouth Africa Delivery, iDaily Domestic Delivery, I-European Domestic Delivery

I-Orlistat powder

Akukho kalo
5.00 ngaphandle kwe 5 ngenxa ye 1 ireyithingi abathengi
SKU: 96829-58-2. Udidi:

I-AASraw ikunye kunye nokukwazi ukuvelisa kwigram ukuya kwinqanaba le-Orlistat powder (96829-58-2), phantsi kommiselo weCGMP kunye nolawulo lwekhwalithi ephezulu.

I-Orlistat powder i-derived content of lipstatin, i-inhibitor enamandla ye-pancreatic lipases ehlukeneyo kwi-british Streptomyces toxytricini. I-Orlistat isilwanyana esilungiselelwe ukunyanyisa ukukhuluphala. Nangona kunjalo, ngenxa yobunzima bayo obuqinileyo ukuzinza, i-orlistat yonyulwa kwi-lipstatin ekuphuhliseni njengesicatshulwa sokulwa nokukhuluphala.

Ingcaciso yeMveliso

Ividiyo ye-Orlistat powder


I-Orlistat iphambili ye powder Characters

igama: I-Orlistat powder
CAS: 96829-58-2
I-molecular Formula: C29H53NO5
Isisindo somzimba: 495.7
Melt Point: 50 ° C
Isitoreji sokugcina: 2-8 ° C
umbala: Powder


Igama lomkhiqizo: Orlistat

IUPAC Name: [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate

Orlistat Isingeniso

Ingaphezulu kwesiqingatha sehlabathi labantu abaye bazama inkqubo yokulawula ubunzima, njengokutya, ukusebenzisa, ukuhlinzwa, okanye unyango. Zonke ezi mphulo zokulahlekelwa kwesisindo zisebenza kuphela xa uthembekileyo kubo kwaye ulandela imiyalelo ekugqibeleni. Nangona kunjalo, ukukhetha ukuhlinzwa okanye amayeza angase ahlasele xa ungathathi amanyathelo.

Isakhiwo seKhemikhali se-Orlistat (i-3-D)

Isakhiwo seKhemikhali se-Orlistat (i-2-D)

Iimpawu zeChimicals ze-Orlistat

Igama lomhlaba Ixabiso lePropati
I-Unit Counter-Bonded Unit Count 1
Isotope Atom Count 0
Ukubala okungabonakali kweBond Stereocenter Count 0
Ukubalwa kweBond Stereocenter Count 0
Ukubala okungenakuchazwa kwe-Atom 0
Count Count Stereocenter Count 4
Count Atom Count 35
Ukuhlawula ngokusemthethweni 0
Inkomfa iCanonicalized Liyinyaniso
XLogP3-AA 10
IMisa eyiyo 495.392 g / mol
IMasaisotopic Mass 495.392 g / mol
Indawo ye-Topological Polar Area 81.7 A ^ 2
Ukunyaniseka 579
Isibalo seBond yokuguquguquka 23
I-Hydrogen Bond Acceptor Count 5
I-Hydrogen Bond uMniki-mali 1
Isisindo somzimba 495.745 g / mol

Inkcazo elula ye-Orlistat powder

Enye ye ukunyuka kwamayeza ukuba uza kufumana kwi-quest yakho ukufumana izidakamizwa zokulawula ubunzima obuninzi kakhulu yi-Orlistat. Kule ngcebiso ye-Orlistat, uza kufumana ulwazi olubalulekileyo, kuquka oko kusebenzayo, nendlela ekufuneka isetyenziswe ngayo, ngoko unokwenza isigqibo sokuba ngaba kukukhetha okokulungileyo.

I-Orlistat yintoni?

I-Orlistat, ethengiswa njengemithi yonyango phantsi kwegama lezorhwebo Xenical, yilapho ilahleko yesisindo sokulahlekelwa kweziyobisi ezenzelwe ukunyanga imiba enzima yobunzima, njengento yokukhuluphala, kunye nezinye izimo ezinxulumene nesisindo. Yenzelwa i-GlaxoSmithKline njenge-drug-counter-counter-drug ebizwa ngokuba ngu-Alli kumabini ase-United States nase-United Kingdom.

Iifom ze-Orlistat ze-generic ziyafumaneka emazweni amaninzi. Ukususela kwi-2000, ihlelwe njenge-S3 kwi-anti-counter-counter-counter-medication e-Australia. Ukuvunyelwa kwe-Orlistat njengesixhobo sokugqithisa ngokuphindaphindiweyo kwakuyi sifundo e-United States. Kwakuchaswa ngokuphindaphindiweyo malunga nokusebenza kunye nokukhuselwa yiqela leqela lokukhuthaza abathengi elibizwa ngokuba yiSizwe soLuntu.

Izenzo ze-Orlistat njenge-lipase inhibitor, ngokuqhelekileyo ithetha ukuba inqanda ukutsalwa kwamafutha ekudleni, ngoko ukunciphisa inani leekhalori ozithathayo. Njengamanye amaninzi amayeza, Orlistat lenzelwe ukusetyenziswa ngokubambisana nezinye iindlela zokuphila ezifana nokuzilolonga nokutya. Uphando lwezonyango lubonisa ukuba abantu abambelele kule nhlanganisela bemi ithuba lokulahlekelwa ezimbini ukuya kweethathu kilogram ngaphezu kwezo ezingabandakanyi izilwanyana kwisifo sabo sokulahlekelwa kwesisindo.

Enye yeempawu ezinqwenelekayo malunga ne-Orlistat kukuba akusikuncedi nje ukulahlekelwa isisindo kodwa iyanciphisa ngokunyanisekileyo uxinzelelo lwegazi. Ukongezelela, le nkunkuma yokulawula isisindo ithathwa ukuba inqanda ukuqala kohlobo lwe-2 sikashukela kubantu abanobukhulu ngendlela efanayo nendlela yokuphila eyenziwa ngayo.

Nangona kukho iintlobo ezininzi ze-Orlistat ezivuyisayo malunga nazo, zikhona nezinye iziphumo zempembelelo ze-Orlistat ukuthobela ingqalelo. Igalelo eliphambili elibhekisiwe kakhulu elibiweyo le pilisi yokulahlekelwa kwesisindo i-steatorrhea. Esi sifo sesisu esisetyenziswe ngamafutha, izihlalo ezikhululekile. Iimpawu, ngenhlanhla, zinciphisa ngexesha.

I-Orlistat Mechanism of action

I-Orlistat iyinamandla ye-Intestinal Lipase Inhibitor. Esi sidakamizwa siyi-inhibitor esisebenzayo yokuvuselela i-lipases. Isilwanyana senza isibophelelo esinama-covalent kunye nesayithi e-serine esebenzayo kwi-pancreatic kunye ne-gastric lipases, ngaloo ndlela inqanda izenzo kunye nokuthintela i-fat from diet to be hydrolyzed and absorbed. (NCI04).

Ngendlela elula, i-Orlistat iququzelela ukulahleka kwesisindo ngokunciphisa i-pancreatic kunye ne-gastric lipases, eziyi-enzyme ebalulekileyo emathunjini aphuhla i-triglycerides. Xa ezi lipases zivaliwe, i-hydrolysis ye-triglycerides ukusuka ekudleni kwakho ibe yi-fatty acids acids inqandekile.

Iipilisi zokutya zithathwa ngomlomo kwaye zithathwe kanye; I-lipase inhibition yendawo yenzeke kwiphepha le-GI. Inani elincinci lonyango lixhomekeke emzimbeni, ininzi yesilwanyana ikhutshwe ngamagqabi.

Uphando olutshanje lufumene i-Orlistat ibe namandla ekuvimbeleni i-enzyme ebandakanyekayo ekusasazeni kweeseli zomhlaza. Nangona kunjalo, iziphumo ezinobungozi ezinobungozi (ezifana nokuvimbela ezinye iiseli ezingalindelekanga okanye ukungafumaneki kakuhle kwemvelo) ziphazamisa ukusetyenziswa kwazo njenge-aditumor agent efanelekileyo. Kwisifundo esithile, abaphandi bathatha indlela yokusebenzisa iiproyomics ukufumana iithagethi ezintsha zamachiza, kuquka ezijoliswe kuzo.

Kwimizuzu eqhelekileyo yemithi ye-120 mg i-3 amaxesha ngosuku ngaphambi kokutya, i-orlistat i-pilish loss loss ikhusela i-30 ekhulwini lamanqatha okunesondlo ekungeneni kumzimba. Ukuthatha amanani amaninzi akunikezi miphumo emandla kakhulu.

Ukusetyenziswa kweOrlistatpowder

I-Orlistat isetyenziswe njengesigxina sokulawula isisindo. Yinto ekhethekileyo yokukhetha abantu abagqithiseleyo okanye abagqithiseleyo. Le pilisi yokulahlekelwa kwesisindo iyanconywa ukuba isetyenziswe ngabantu abaneengxaki zonyango ezinxulumene nesisindo. Uthembisa ukunceda abantu bangabi nciphise ubunzima, kodwa kunceda ekuthintele ukuba bazuze ubukhulu abalahlekileyo. Ngokwenza njalo, kunceda ukunciphisa umngcipheko we-high blood pressure, isifo sikashukela, isifo senhliziyo, kunye nezinye izingozi zempilo ezinxulumene nokukhuluphala.

Umlinganiselo wokulahleka kwesisindo emva kokuthatha i-Orlistat ihluka ukusuka komntu omnye ukuya kwenye. Abaphengululi abaqhuba izilingo zonyango ezidlulileyo ngonyaka bafumanisa ukuba phakathi kweepesenti ze-35.5 kunye neepesenti ze-54.8 zezifundo eziphumelele ukufezekisa i-5 ipesenti enkulu ekunciphiseni umzimba, nangona kungabikho konke ukulahleka kweyona nto ilahlekile. Mayelana ne-16.4% -24.8 yezifundo eziphunyezwe ukufezekisa ubuncinane i-10 yeepesenti ezinciphisa umzimba. Xa izifundo zayeka ukuthatha i-Orlistat, inani elikhulu laphinde laphindela kwi-35 ekhulwini lobunzima ababenakho ukulahlekelwa.

Isisombululo se-Orlistat

I-Orlistat iza ngendlela ye-turquoise, i-gelatin i-capsules ezinzima eziqulethe i-pellets ye powder kunye no-120-mg. Imilinganiselo yansuku zonke ekhuthazwayo iifomsile ezintathu ngosuku. Akufanele uthathe zonke iipilisi ekuhambeni, kodwa kunoko thabatha iipilisi nganye ngesidlo esisisiseko esinezifo, oko kukuthi, esinye sesidlo sakusasa, esinye sesidlo sasemini, kunye nesinye isidlo sakusihlwa. Unokuthatha ipilisi nganye ngokutya okanye ukufikelela kwiyure enye emva kokutya. Ukuba ngaba ukutya kungasweleki, okanye ukuba isidlo sakho asinayo i-fat, i-Orlistat dose ingashiywa. Imilinganiselo engentla kwimiyalelo yansuku zonke ekhuthazwayo ayifumanekanga ukubonelela nayiphi na inzuzo eyongezelelweyo.

I-Orlistat iphumelele kakhulu xa ihlanganiswe nezinye izicwangciso zokulahlekelwa kwesisindo ezifana nokunamathela kwisondlo sokutya okunokutya okunokutya, okuncitshisiweyo kunye nokuzivocavoca rhoqo. Uyacetyiswa ukuba uthathe ipilisi yokulahlekelwa kwesisindo kunye nesidlo esineenkcukacha ze-30 iikhalori zeepilisi kwiitye. Imiphumo yesilwanyana ibonakala ngokukhawuleza emva kweeyure ze-24-48 emva kokuthatha umthamo.

I-Orlistat ifumaneke ukuba isebenze ekunciphiseni ukuxutywa kwamavithamini athile anelumnumzana kunye ne-beta-carotene. Ngaloo ndlela, abantu abathatha ipilisi bayacetyiswa ukuba bayithathe kunye ne-vitamin amaningi enezithambile ezinamafutha amanelisekile ukuqinisekisa ukutya okwaneleyo. Kunconywa ukuba i-vitamin supplement ithathwe ubuncinane iiyure ezimbini ngaphambi okanye emva kokuthatha i-Orlistat.

Ngokuphathelele ezo zigulane zithola unyango lwe-cyclosporine, ziyacetyiswa ukuba zenze i-cyclosporine ubuncinane iiyure ze-3 emva kokuthatha i-Orlistat. Kwabo bafumana unyango lwe-levothyroxine, bakhuthazwa ukuba baphathe i-levothyroxine unyango ubuncinane kwii-4 iiyure emva kokuthatha i-Orlistat. Abo bathatha ii-Orlistat kunye ne-levothyroxine kufuneka baqwalaselwe ngononophelo malunga noshintsho kwimisebenzi ye-thyroid.

OrlistatPrecautions

Ngaphambili, i-orlistat yayithathwa ngokungqongqo phantsi kwemigqaliselo yogqirha okanye i-pharmist. Nangona kunjalo, kwi-2007, i-US Food and Drug Administration yavuma ukuba i-market-counter-counter market, ngoko ke yenza ukuba ibe khona kuwo wonke umntu.

Khangela nayiphi na impendulo

Ngaphambi kokuba uthathe le michiza, kucetyiswa ukuba uthethe ugqirha wakho malunga naluphi na ukuphendula kwe-hypersensitive behavior. I-Orlistat iqukethe izithako ezingasebenzi, ezingenakukuthandayo, ezikhokelela ekusebenziseni iimpawu ezinzima kunye nemiphumo emibi. Ezinye zazo ziquka i-cellulose, i-microcrystalline, i-gelatin, i-silica, kunye ne-sodium isitashi ye-glycolate.

Cinga ngembali yakho yonyango

Kufuneka uhlanganyele kunye nekhemistiki okanye ugqirha wakho malunga naluphi na uhlobo lwezonyango onokuba nalo. Oku kungenxa yokuba i-orlistat iyaphikiswa kwiimeko ezingezizo kunye neengxaki, ngakumbi ezo zidibene nokugaya.

Ukuba unobandezeleka kuyo nayiphi na imiqathango engezantsi, kucetyiswa ukuba ufune ulwazi olungakumbi kwi-professional.

Malabsorption syndrome

Oku kuyinto engafanelekiyo ekujongeni ukungenayo okwaneleyo kwezondlo zokutya kunye neenkqubo zeGIT. Kufuneka uqaphele ukuba i-orlistat ngokwayo isebenza ngokuthintela ukungcola kwamafutha. Ngako oko, oku kuza kugqitywa ngakumbi kunomntu othabatha iziyobisi, kodwa aphethwe yi-malabsorption syndrome.

Ingxaki yesifo okanye i-cholestasis

Le yimeko apho kukho ukuvinjelwa kwe-bile kwi-isibindi. Zininzi Iingxelo edibanisa i-listlist kwisibi sobungozi obukhulu, nangona kwenzeka kwiimeko ezinqabileyo okanye phantsi kwesilinganiso esiphezulu.

Isifo seGallbladder

Oku kubandakanya i-cholecystectomy kunye ne-syndromes edibeneyo.

Ezinye izimo zempilo omele uzixelele kwi-pharmist yakho zibandakanya ukusuleleka kwi-HIV, izifo ze-thyroid, iigciwane zamathambo, ukuxhatshazwa, okanye i-pancreatitis. Xa unqabana okanye udibanisa, i-orlistat ingaphelela ekungalingani nonyango lwe-antiepileptic ngokuphazamisa ukufunyanwa.

Izidlo zokutya

Ezinye zezi ngxaki zi-bulimia kunye ne-anorexia. Kwakhona, akukho mfuneko yokuthatha i-orlistat ukuba ungeyongaphezulu.

Amanye amayeza

Kucetyiswa ukuba uxelele ugqirha wakho ukuba unamanye amayeza ngokukodwa oku kunokukhusela isistim somzimba. Ukusebenzisana kweziyobisi ngeziyobisi kuya kuphazamisa i-pharmacokinetics, ekhokelela ekunyuseni okanye kunyuka kwefuthe kuwo. Ngokomzekelo, i-orlistat iya kuhlala iphazamise indlela yokusetyenziswa kweziyobisi ezibekwe ukufakelwa komzimba.

Ukuba u-cyclosporine, ugqirha wakho uya kukuxelela ukuba ugweme i-orlistat. Nangona kunjalo, unako ukulawula kuphela ngemigaqo eqinile. Ukuze ube kwicala elikhuselekileyo, kufuneka uthabathe ubuncinane ubuncinane iiyure ezimbini phambi kokusetyenziswa kwezidakamizwa zokulawula ubunzima okanye iiyure ezimbini emva koko.

Ukongezelela, kufuneka ubhekiselele yonke imirhumo kadakamizwa kunye nemigomo engagunyazisiyo, izongezelelo zondlo, iivithamini, i-anticoagulants, okanye iimveliso zemithi ongayithatha.

Abafazi abakhulelweyo nabancelisayo

La mayeza okulawulwa kwezobunzima akulona oomama abalindeleyo, nabani na oceba ukukhulelwa, okanye ukuncelisa. Isilwanyana akunakwenzeka ukuba sibe nefuthe lokulahlekelwa kwesisindo kwaye siya kugqiba ukulimaza umntwana.

Nangona kungekacaci ukuba i-orlistat idlulela emathunzini kanina, ungathanda ukuyiphepha kwaye uzive ukhuselekile, kunokuba uxolo.

Diabetics

I-Orlistat yintoni nawuphi na umntu onesifo sikashukela oya kufuna ukuphucula nokulawula iswekile yegazi nokuphucula ukunyamezela kwe-glucose. Nangona kunjalo, kuya kufuneka ubeke iliso kwinqanaba lezeshukela rhoqo kwaye u tyelele rhoqo ugqirha. Ukwenza okunjalo kukunceda ukwazi ukuba ulungelelanise unyango lwesifo sikashukela, ukutya okulungileyo, kunye nenkqubo yokusebenzisa.

Iimpembelelo zecala le-Orlistat

Njengamanyango amaninzi, i-orlistat ineempembelelo zayo. Isiphumo esisezantsi saso sisoloko sigqitywa kwimikhwa yobomi. Nangona kunjalo, oku kungabonakala kuphela ngeeveki zokuqala zokuthatha isisindo sokulahleka kwesisindo.

Kwabanye abantu, iimpawu zingaphantsi kwexesha kwabanye; ingaqhubeka nokuthatha i-orlistat. Ngeli nqanaba, kulungile ukuxelela ugqirha wakho. Ukuthobela ngakumbi ukutya okuncinci, kunokwenzeka ukuba yimiba emibi ukunciphisa.

Nazi ezinye iziphumo eziqhelekileyo;

Steatorrhea

Nangona ingozi, i-steatorrhea kukukho kweoli kunye namafutha angaphezulu kwi-stool. Ekubeni i-orlistat inqanda i-lipases, akuyi kubakho i-absorption ye-fatty acid acids. Ngenxa yoko, iifesi ziza kubonakala zi-oily kunye ne-bulky.

Ukulawula le mphumela, umntu kufuneka agweme ukutya okucebile ngeekhalori namaqondo aphezulu amanqatha. Ngokomgangatho we-FDA, isixa kufuneka sibe phakathi kweeyunithi ze-0.53 kwaye ungadluli i-30%.

Flatulence

Kwiimeko ezininzi, igesi iyaphuma kunye nokukhutshwa kweoli. Uya kufuneka uhlolisise iimpahla zakho okanye iingubo zangaphantsi ngeendlela zokuhamba ngamanzi.

  • Ukungabikho kwamaFecal

Ukunyuka, ukukhawuleza, kunye nokuhamba rhoqo

  • Ukuphazamiseka kunye nentlungu esiswini
  • Umjikelezo ongaqhelekanga wokuhamba
  • Amanqanaba eshukela ephantsi

Oku kuqhelekileyo kubantu abanesifo sikashukela sephepha II.

  • Ukulimala kwesibindi

Iimeko ezinjalo ziqabile kodwa ziza kwenzeka xa unengxaki yebindi, okanye uthatha umlinganiselo ophezulu. Kwi-2010, i-FDA yayiquka isilumkiso sokukhusela kwiilebula ze-orlistat, ezibonisa umngcipheko wokulimala kwamabindi.

Nangona kunjalo, esi siphumo sangasese siseyi-mpikiswano esicinga ukuba enye into yokuphonononga eyapapashwa kwiBritish Medical Journal yabonisa ngenye indlela.

Ezinye zezibonakaliso zezifo zesibindi ziquka ukuhlanza, ubuhlungu besisu, isikhumba esiluhlaza kunye nomchamo omnyama.

Ukuphendulwa kwemizwa

Kuyinto engavamile ukufumana nayiphi na i-hypersensitivity okanye i-feedback response xa uthatha ipilisi yokulahleka komzimba. Kwabanye abantu, izithako ezingabonakaliyo ezifunyenweyo kwisicatshulwa zingabangela i-nausea, ukubetha, ukukhawuleza, ukuvuvukala komzimba, ukuphefumula ubunzima, okanye utywala.

Ezinye iimpembelelo eziqhelekileyo eziqhelekileyo ziquka ukuxhalaba, intloko, ukunqanda, ukuxhatshazwa kwamathambo, ukhathala, isondlo esincinci, kunye nama-gallstones. Ukuba ufumana iimpawu ezinzima, kufuneka uxelele ugqirha wakho ngokukhawuleza okanye uxelele Inkqubo yeNgxelo ye-FDA.

Isigqibo sokugqibela kwi-Orlistat powder

Nangona i-orlistat inemiphumo emibini yecala, yinto ephuculweyo yokulahlekelwa kwindleko eya kuzisa iziphumo kwiiveki ezimbini. Imfihlelo yokuzuza kwesi siza kulandela imiyalelo, ukuqonda izilumkiso kunye nokujonga ukutya kwakho.

Njengoko uthatha i-orlistat, kubalulekile ukuba ulandele inkqubo yesondlo esifanelekileyo, udle amanqatha amaninzi, iikhalori eziphantsi kwaye usebenzise rhoqo. Ukutya okufanelekileyo kufuneka kufake iziqhamo, imifuno kunye neenqolowa. Ukongezelela, kufuneka ukongeze ukutya kwakho kunye neemveliso ezifunekayo ze-multivitamin ukususela kwi-orlistat inqanda ukuxutywa kwamavithamini aneenqatha.

Xa ungathandabuzeki, ungaqhagamshelana nekhemistiki okanye ugqirha ukuba ufumane imiyalelo eyongezelelweyo. Ngaphandle koko, unokuqhagamshelana ne-US Food and Drug Administration kuyo nayiphi na imibuzo okanye ingxelo yecala lokusongela ubomi, ezingabhalwanga.


Indlela yokuthenga I-Orlistat powder (96829-58-2) kwiAASraw

1.Qhagamshelana nathi nge-imeyile yethu inkqubo yophando, okanye i-skype ye-intanethiummeli wenkonzo yamakhasimende (CSR).
2.Ukusibonelela ngobuninzi bakho kunye neadesi.
I-3.I-CSR yethu iya kukunika isingeniso, ixesha lokuhlawula, inombolo yokulandelela, iindlela zokuhambisa kunye nomhla wokufika oqikelelwayo (i-ETA).
I-4.Inkokhelo eyenziwe kwaye iimpahla ziya kuthunyelwa kwiiyure ze-12 (Ukuze ulandelwe ngaphakathi kwe-10kg).
5.Goods zifunyenwe kwaye zinike izimvo.

ISIQINISEKISO NESIBONELELO:

Le nto ithengiselwe uKwenziwa koPhando kuphela. Imigaqo yokuthengisa Faka isicelo. Ayisetyenziselwa uBuntu, okanye oNyango, iZilwanyana, okanye abaNtu.


=

IAAA

I-COA 96829-58-2 Uhlobo lwe-Or Ordat AASRAW

HNMR

I powder Orlistat emfutshane (96829-58-2) hplc =98% | I-AASraw I-Fat ilahlekile i powder

I-AASraw inikezela ubungcwele 99% Orlistat powder eluhlaza kubakhi bomzimba okanye iilabhu zangaphantsi zokusetyenziswa komlomo.

Recipes

Iziqulatho kunye nokuqulunqwa kwemveliso

I-anti-Obesity powder: Cetilistat powder vs Orlistat powder

Yonke into omele uyazi ngayo malunga ne-Orlistat powder yokulahleka kweoli

Umthombo wemvelo we-Orlistat powder yokulahleka kwesisindo-I-fat loss loss drug ifanele uyazi !!!

Uluhlu

Zhi J, Melia AT, Eggers H, Joly R, Patel IH (1995). "Ukuhlaziywa kwe-systemic absorption of orlistat, i-lipase inhibitor, kumavavolontiya anempilo". J Clin Pharmacol. 35 (11): 1103-8

  1. Garcia SB, Barros LT, Turatti A, et al. I-arhente yokuchasene nokugqithisa i-Orlistat inxulumene nokwandisa kwiimpawu ze-colonic preneoplastic marker kwiirats eziphathwe ne-carcinogen ye-chemical. I-Lett yeCarcer. 2006; 240: 221-4.
  2. I-FDA iyavuma (i-orlistat 60 mg capsules) I-Over-The-Counter "(PDF) (Ukhuseleko). PRNewswire. 7 Februwari 2007
  3. Mittendorfer B, Ostlund RE, Jr, Patterson BW, et al. I-Orlistat inqanda ukutywala kwe-cholesterol yokutya. Obes Res. 2001; 9: 599-604
  4. UPeng-Yu, uYang; Kai, Liu; Mun Hong, Ngai; J.Lear, uMartin; R.Wenk, Markus; S.Qin, Yao (2010). "Ukuxilongwa kweproteome esekelwe kwintsebenzo yezinto ezikhoyo zamatye e-Orlistat-i-FDA evunyelwe izidakamizwa kunye nemisebenzi yokulwa ne-tumor". Umbhalo we-American Chemical Society. 132 (2): 656-66.